Ascendis Pharma A/S (NASDAQ:ASND) Stock Price Down 5.1% – Should You Sell?

Ascendis Pharma A/S (NASDAQ:ASND)’s share price fell 5.1% on Thursday . The company traded as low as $126.38 and last traded at $127.98. 108,859 shares traded hands during trading, a decline of 74% from the average session volume of 416,135 shares. The stock had previously closed at $134.87.

Analyst Ratings Changes

A number of research firms recently issued reports on ASND. Bank of America lifted their target price on Ascendis Pharma A/S from $175.00 to $191.00 and gave the company a “buy” rating in a report on Monday, September 23rd. Cantor Fitzgerald reiterated an “overweight” rating and issued a $170.00 price objective on shares of Ascendis Pharma A/S in a research note on Friday, November 15th. Stifel Nicolaus upped their target price on shares of Ascendis Pharma A/S from $200.00 to $207.00 and gave the stock a “buy” rating in a research note on Friday, November 15th. StockNews.com upgraded shares of Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a report on Wednesday, November 20th. Finally, Wedbush reissued an “outperform” rating and issued a $181.00 price objective on shares of Ascendis Pharma A/S in a research report on Friday, November 15th. Two research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Ascendis Pharma A/S presently has a consensus rating of “Moderate Buy” and a consensus price target of $192.07.

Ascendis Pharma A/S Stock Down 1.4 %

The firm has a fifty day simple moving average of $132.95 and a 200-day simple moving average of $133.55. The company has a market cap of $8.07 billion, a PE ratio of -16.47 and a beta of 0.65.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in ASND. Wilmington Savings Fund Society FSB purchased a new position in shares of Ascendis Pharma A/S during the third quarter worth approximately $30,000. GAMMA Investing LLC grew its position in Ascendis Pharma A/S by 58.0% during the 4th quarter. GAMMA Investing LLC now owns 583 shares of the biotechnology company’s stock worth $80,000 after purchasing an additional 214 shares during the last quarter. Signaturefd LLC increased its stake in Ascendis Pharma A/S by 13.2% in the third quarter. Signaturefd LLC now owns 686 shares of the biotechnology company’s stock valued at $102,000 after purchasing an additional 80 shares during the period. Pursue Wealth Partners LLC purchased a new stake in shares of Ascendis Pharma A/S in the third quarter valued at about $217,000. Finally, Rhumbline Advisers boosted its stake in shares of Ascendis Pharma A/S by 10.3% during the second quarter. Rhumbline Advisers now owns 1,533 shares of the biotechnology company’s stock worth $209,000 after buying an additional 143 shares during the period.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.